Pharma BD Deal Intelligence
Endo characterized the AMS divestiture as accelerating its transition to a specialty pharmaceuticals company and improving balance-sheet flexibility.
We believe the businesses Boston Scientific is acquiring fit well into the company's existing urology business and additional focus from Boston Scientific can…
Boston Scientific closed the $1.6B AMS deal earlier than expected, immediately consolidating its position as the largest urology device company in the US.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Boston Scientific acquired Endo's AMS Men's Health and Prostate Health businesses for $1.6B upfront plus up to $50M based on 2016 sales, advancing Endo's transition to specialty pharma. Closed August 4, 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health) (this deal) | 2015 | $1.6B | 82 |
| Boston Scientific Corporation / BTG plc | 2018 | $4.2B | 78 |
| Boston Scientific Corporation / Advanced Bionics Corporation | 2004 | $740M | 26 |
| Boston Scientific Corporation / Vertiflex, Inc. | 2019 | $465M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2015 deals · Boston Scientific Corporation deals · Other deals